Latest News
CEL Corporation
- CEL-SCI reports survival data from Multikine cancer study By Investing.com
- Cellcom Israel Ltd. Estimates – TASE:CEL
- Updated CARTITUDE-2 Data Support Earlier Cilta-Cel Use in Multiple Myeloma
- Prula-cel Shows Early Promise in Lupus
- Caribou Drops Vispa-Cel, CB-011 CAR-T Programs, Eyes Sale
- Caribou Biosciences Discontinues Development for Vispa-cel & CB-011 CAR-T Cell Therapy Programs
- Visual abstract | DALY 2-EU primary analysis: Zamto-cel in 2L transplant-ineligible patients with R/R LBCL
- Bridging therapy response and type as determinants of cilta-cel outcomes in relapsed/refractory multiple myeloma
- Single Infusion of Rese-Cel Yields Meaningful Responses Off Immunomodulators in Phase 1/2 RESET-MG Trial
- Adicet’s prula-cel shows 50% complete renal response rate in Phase I lupus nephritis study
- Cilta-Cel Shows Long-Term Treatment-Free Remissions in Lenalidomide-Refractory Myeloma
- Anito-Cel Delivers Durable Responses With Low Neurotoxicity in RRMM
Headlines from the last 30 days, linking to the original publishers. See all market news →